Introduction: VIDATOX® 30CH is a homeopathic product obtained from the venom of the Cuban scorpion Rhopalurus junceus. It allows improving the quality of life of people suffering from cancer or any other disease in which the inflammatory process prevails.

Objective: To assess the effect of VIDATOX® 30CH in the relief of pain and other symptoms of patients suffering from diseases with an inflammatory component.

Methods: A prospective longitudinal study was carried out with 2541 patients who attended LABIOFAM's medical consultations during the period between 2011 and 2016 and were treated with VIDATOX® 30CH. The variables taken into account were type of disease, main symptom as reason for consultation, time at which improvement of the main symptom started, and adverse events. The characterization of the sample was carried out through the use of descriptive measures and the determination of the 95% confidence interval. Pearson's chi-square was used to compare the clinical evolution of patients by disease. McNemar's test was used to determine the difference in proportions before and after. Analysis of variance was used to compare the time at which patients experienced improvement of the main symptoms.

Results: Patients with oncological diseases predominated (2261, 88.98%), followed by degenerative diseases (132; 5.19%). Pain was the most commonly reported symptom (1431; 56.32). The majority of patients were administered VIDATOX® 30CH three times a day (1389, 54.7%). 96.92% of these patients reported improvement in pain. On average, the improvement of the main symptoms started in 74.79 days. 0.95% of the patients presented mild and transient adverse events.